SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Accumulated Depreciation data on file, last reported at $18.1 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 18.27% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 18.27% YoY) and the FY2025 annual result came in at $17.5 million, up 20.19% from the prior year.
• Accumulated Depreciation climbed to $18.1 million in Q1 2026, from $17.5 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $18.1 million in Q1 2026 to a low of $3.8 million in Q1 2022.
• A 5-year average of $11.7 million and a median of $12.9 million in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation soared 94.98% — and 2026, when it grew 18.27%.
• Tracing SABS's Accumulated Depreciation over 5 years: stood at $6.3 million in 2022, then surged by 57.87% to $9.9 million in 2023, then jumped by 47.04% to $14.6 million in 2024, then gained by 20.19% to $17.5 million in 2025, then advanced by 3.47% to $18.1 million in 2026.
• The last three Accumulated Depreciation figures came in at $18.1 million (Q1 2026), $17.5 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.